Cardium, InnerCool complete $5M commercial financing
Cardium Therapeutics and its subsidiary, InnerCool Therapies, have completed a $5 million commercial credit facility with Life Sciences Capital to support the launch of InnerCool’s new product lines for patient temperature modulation and other ongoing product development activities.

Christopher J. Reinhard, chairman and CEO of Cardium and InnerCool, said the “two next-generation systems are designed to advance InnerCool to the forefront of the emerging field of therapeutic hypothermia.”

Cardium and InnerCool, both headquartered in San Diego, are medical technology companies focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular and ischemic-related indications.